Drug Designation, Patents, Milestone Payment, Quarterly Result, and Medical Study - Research Report on The Medicines Company, VIVUS, Isis, HeartWare, and Masimo
NEW YORK, November 20, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting The Medicines Company (NASDAQ: MDCO), VIVUS Inc. (NASDAQ: VVUS), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), HeartWare International Inc. (NASDAQ: HTWR), and Masimo Corporation (NASDAQ: MASI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
The Medicines Company Research Report
On November 12, 2013, The Medicines Company announced that the US Food and Drug Administration (FDA) has designated oritavancin, the Company's investigational Antibiotic, as a Qualified Infectious Disease Product (QIDP). According to the Company, the QIDP designation provides oritavancin priority review by the FDA, eligibility for FDA's "fast track" status, and an additional five years of exclusivity upon approval of the product for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Further, The Medicines Company stated that the QIDP designation was granted on the basis of the Generating Antibiotic Incentives Now (GAIN) Act, included in the FDA Safety and Innovation Act (FDASIA) that was signed into law in 2012. The Company reported that it intends to submit a New Drug Application to the FDA in Q4 2013 for the use of oritavancin in ABSSSI caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
VIVUS Inc. Research Report
On November 13, 2013, VIVUS Inc. (VIVUS) announced that the US Patent and Trademark Office has issued US Patent Nos. 8,580,298, covering compositions of Qsymia, and 8,580,299, covering methods for effecting weight loss using Qsymia. Seth H. Z. Fischer, CEO of VIVUS, commented, "The issuance of these new Qsymia patents is an important achievement for VIVUS." Fischer added, "Extension of our patent coverage by an additional nine years adds significant value to the Qsymia franchise. The new patents provide us with a greater opportunity to promote Qsymia as a highly effective therapy of choice for obese patients and for overweight patients with one or more comorbidities." The Full Research Report on VIVUS Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Isis Pharmaceuticals, Inc. Research Report
On November 15, 2013, Isis Pharmaceuticals, Inc. (Isis) announced that it has earned a $5 million milestone payment from GlaxoSmithKline in relation to the designation of ISIS-GSK4Rx as a development candidate. Isis reported that the ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease. B. Lynne Parshall, Chief Operating Officer at Isis, said, "Our collaboration with GlaxoSmithKline has been very productive resulting in three novel antisense drugs in our pipeline." Parshall continued, "We look forward to advancing ISIS-GSK4Rx into the clinic and providing more information on the target and disease opportunity, which we are very excited about." The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
HeartWare International Inc. Research Report
On November 7, 2013, HeartWare International Inc. (HeartWare) released its Q3 2013 results. HeartWare registered net revenues of $54.8 million in Q3 2013, up 139.7% YoY. The Company posted net loss of $11.4 million in Q3 2013, compared to net loss of $25.0 million in Q3 2012. HeartWare reported diluted loss per share of $0.69 in Q3 2013, compared to diluted loss per share of $1.75 in Q3 2012. Doug Godshall, President and CEO of HeartWare, stated, "Our results for the third quarter reflect continued positive trends in the commercial launch of the HeartWare System in the US, following approval from Food and Drug Administration (FDA) late last year, as well as continued strong support from our international customers." The Full Research Report on HeartWare International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Masimo Corporation Research Report
On November 5, 2013, Masimo Corporation (Masimo) announced a new study in the Journal of Critical Care which shows that the Company's noninvasive PVI can be helpful for clinicians to accurately assess fluid responsiveness in mechanically ventilated patients in the early phase of septic shock in the emergency room. Steve Barker, M.D., Ph.D., Interim Chief Medical Officer of Masimo, explained, "This study demonstrates the practical and cost-effective advantage of PVI, particularly for physicians for whom time and ease of use are of the essence. The findings also add to the growing body of evidence that shows the efficacy of PVI across a wide range of patient populations." The Full Research Report on Masimo Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner